UCI Health | Strategic Alliance Partners

Latest from UCI Health


Dr. Ou on the FDA Approval of Pembrolizumab in SCLC

June 18, 2019

Sai-Hong Ignatius Ou, MD, PhD, Health Science Associate Clinical Professor, University of California, Irvine, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, California, discusses the FDA approval of pembrolizumab (Keytruda) in small cell lung cancer (SCLC).

Fulvestrant/Anastrozole Combo Improves Survival in Metastatic HR+ Breast Cancer

March 29, 2019

The frontline combination of fulvestrant and anastrozole resulted in a sustained benefit in progression-free survival and a significant improvement in overall survival compared with anastrozole alone in patients with postmenopausal, HR–positive metastatic breast cancer, according to long-term results of the SWOG S0226 trial.

x